Valor202020212022202320242025TTMGastos comerciales, generales y administrativos68.84 M97.59 M106.9 M121 M142.79 M166.99 M166.99 MInvestigación y desarrollo13.02 M16.29 M19.94 M21.04 M24.8 M27.56 M27.56 MBeneficio operativo2.37 M-7.85 M-17.06 M-6.46 M4.52 M11.04 M11.04 MTotal de ingresos no operativos672 K272 K1.07 M4.1 M5.99 M6.33 M6.33 MGastos por intereses, netos de intereses capitalizados13 K4 000366 K600 K614 K630 K630 KIngresos no operativos, una vez deducidos los gastos por intereses665 K216 K609 K3.43 M5.18 M5.75 M5.75 MIngresos/gastos extraordinarios-6 00052 K95 K64 K195 K-44 K-44 KBeneficio antes de impuestos3.04 M-7.58 M-15.99 M-2.37 M10.51 M17.38 M10.18 MParticipación en los beneficios———————Impuestos180 K-111 K721 K814 K148 K859 K—Participación minoritaria———————Otros ingresos/gastos después de impuestos—-7 000-22 K-39 K-43 K-13 K-13 KBeneficio neto antes de actividades interrumpidas2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M16.52 MOperaciones suspendidas———————Beneficio neto2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M16.52 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas2.86 M-7.47 M-16.71 M-3.18 M10.36 M16.52 M16.52 MBeneficio básico por acción0.06-0.16-0.35-0.070.210.330.33Beneficio por acción diluido0.06-0.16-0.35-0.070.20.320.32Número medio de acciones ordinarias45.22 M46.47 M47.13 M47.59 M48.85 M50.34 M201.1 MAcciones diluidas47.28 M46.47 M47.13 M47.59 M51.68 M52.15 M204.33 MEBITDA4.75 M-4.85 M-13.08 M-1.83 M10.02 M22.59 M22.59 MEBIT2.37 M-7.85 M-17.06 M-6.46 M4.52 M11.04 M11.04 MCosto de los ingresos39.95 M50.16 M54.58 M61.94 M65.12 M70.66 M70.66 MOtros costes de producción—————1.04 M—Amortización y depreciación (flujo de caja)2.38 M3 M3.98 M4.63 M5.5 M11.54 M11.54 M
Vericel Corporation
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.